Acadian Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Acadian Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-139,386	Closed	-$352K	–	1958
2023 Q1	$352K	Sell	139,386 -107,287	-43%	-$212K	﹤0.01%	1134
2022 Q4	$459K	Buy	246,673 +225,224	+1,050%	+$562K	﹤0.01%	1058
2022 Q3	$54K	Sell	21,449 -70,663	-77%	-$176K	﹤0.01%	1489
2022 Q2	$178K	Buy	+92,112	New	+$201K	﹤0.01%	1227
2021 Q2	–	Sell	-15,001	Closed	-$106K	–	2269
2021 Q1	$106K	Buy	+15,001	New	+$108K	﹤0.01%	1664

Other funds holding PRTK

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Acadian Asset Management's PRTK Position: Q2 2023 in Review

Acadian Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2023, closing a stake of 139,386 shares — an estimated $352K sold.

Acadian Asset Management first reported a position in PRTK in Q1 2021 and held it in 5 quarters. The position peaked at $459K in Q4 2022. 66 funds tracked by Wall St. Rank hold PRTK as of Q2 2023.

Acadian Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Acadian Asset Management sold 139,386 Paratek Pharmaceuticals, Inc. shares in Q2 2023, an estimated $352K.
Acadian Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2021 and held it in 5 quarters.
Acadian Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $459K in Q4 2022.
66 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2023.

Based on Acadian Asset Management's 13F filing for Q2 2023, filed 7 Aug 2023.